China NMPA Drug Inspection - 17 companies including Hebei Kangyiqiang Pharmaceutical Co., Ltd. - 19 batches of Chinese herbal medicine slices

The Shandong Provincial Food and Drug Administration, under the National Medical Products Administration (NMPA), issued Announcement No. 128 on October 10, 2018 (published November 18, 2019), detailing the outcomes of a comprehensive drug quality inspection. Inspections, carried out by nine drug testing institutions including the Shandong Provincial Institute for Food and Drug Control, identified 20 batches of pharmaceutical products failing to meet established quality standards. Specifically, one batch of drugs from Jiangsu Dahongying Hengshun Pharmaceutical Co., Ltd., and 19 batches of traditional Chinese medicine decoction pieces from 17 companies, including Hebei Kangyiqiang Pharmaceutical Co., Ltd., were deemed substandard. While specific deviations were not detailed, the findings highlighted critical quality non-compliance. In response, municipal food and drug administrations have taken immediate control actions, including sealing, seizing, suspending sales, and recalling the affected products. Investigations have been initiated against the responsible manufacturers and sampled units under relevant drug regulatory laws. Furthermore, enterprises are mandated to thoroughly investigate the root causes of these quality deficiencies and implement corrective measures to effectively mitigate potential risks, with ongoing intensified supervision from regulatory bodies.